NO985231D0 - Forbindelser som fremmer vevsvekst - Google Patents

Forbindelser som fremmer vevsvekst

Info

Publication number
NO985231D0
NO985231D0 NO985231A NO985231A NO985231D0 NO 985231 D0 NO985231 D0 NO 985231D0 NO 985231 A NO985231 A NO 985231A NO 985231 A NO985231 A NO 985231A NO 985231 D0 NO985231 D0 NO 985231D0
Authority
NO
Norway
Prior art keywords
seq
human
cdna
retl
retl3
Prior art date
Application number
NO985231A
Other languages
English (en)
Other versions
NO985231L (no
NO323612B1 (no
Inventor
Michele Sanicola-Nadel
Catherine Hession
Richard L Cate
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of NO985231D0 publication Critical patent/NO985231D0/no
Publication of NO985231L publication Critical patent/NO985231L/no
Publication of NO323612B1 publication Critical patent/NO323612B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO19985231A 1996-05-08 1998-11-09 Ret-ligandb3 (RetL3) for stimulering av neural og renal vekst, nukleinsyrer som koder for polypeptidet, fusjonsprotein samt antistoff som spesifikt binder polypeptidet. NO323612B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1742796P 1996-05-08 1996-05-08
US1930096P 1996-06-07 1996-06-07
US2185996P 1996-07-16 1996-07-16
US4353397P 1997-04-11 1997-04-11
PCT/US1997/007726 WO1997044356A2 (en) 1996-05-08 1997-05-07 RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH

Publications (3)

Publication Number Publication Date
NO985231D0 true NO985231D0 (no) 1998-11-09
NO985231L NO985231L (no) 1999-01-08
NO323612B1 NO323612B1 (no) 2007-06-18

Family

ID=27360789

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19985231A NO323612B1 (no) 1996-05-08 1998-11-09 Ret-ligandb3 (RetL3) for stimulering av neural og renal vekst, nukleinsyrer som koder for polypeptidet, fusjonsprotein samt antistoff som spesifikt binder polypeptidet.
NO20065528A NO324957B1 (no) 1996-05-08 2006-11-30 Anvendelse av monoklonalt antistoff for fremstilling av medikament til behandling av Ret-assosierte lidelser.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20065528A NO324957B1 (no) 1996-05-08 2006-11-30 Anvendelse av monoklonalt antistoff for fremstilling av medikament til behandling av Ret-assosierte lidelser.

Country Status (24)

Country Link
EP (2) EP1757617A1 (no)
JP (1) JP2002515743A (no)
KR (2) KR20060024843A (no)
CN (2) CN1163509C (no)
AT (1) ATE335003T1 (no)
AU (1) AU732392B2 (no)
BG (2) BG109433A (no)
BR (1) BR9710665A (no)
CA (1) CA2253871C (no)
CZ (1) CZ296516B6 (no)
DE (1) DE69736428T2 (no)
DK (1) DK0914339T3 (no)
EA (1) EA002544B1 (no)
EE (1) EE9800377A (no)
ES (1) ES2270465T3 (no)
IL (1) IL126918A (no)
IS (1) IS2361B (no)
NO (2) NO323612B1 (no)
NZ (1) NZ332706A (no)
PT (1) PT914339E (no)
RO (1) RO120343B1 (no)
SK (1) SK286115B6 (no)
TR (2) TR200103297T2 (no)
WO (1) WO1997044356A2 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
EP0846764A3 (en) * 1996-11-27 1998-09-30 Smithkline Beecham Plc Glial cell line-derived neurotrophic factor alpha receptor family
EP0948620A2 (en) * 1996-12-06 1999-10-13 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998036072A1 (en) * 1997-02-18 1998-08-20 Genentech, Inc. Neurturin receptor
US6372453B1 (en) 1997-02-18 2002-04-16 Genetech, Inc. Neurturin receptor
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US6025157A (en) * 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
NZ501423A (en) * 1997-04-17 2002-02-01 Univ Washington Receptors for TGF-beta-related neurotrophic factors and use for treating disease
AU7583898A (en) * 1997-05-20 1998-12-11 Human Genome Sciences, Inc. Gdnf receptors
JP2001527418A (ja) * 1997-05-22 2001-12-25 セフアロン・インコーポレーテツド グリア細胞系由来の神経栄養因子レセプター
WO1998054213A2 (en) * 1997-05-30 1998-12-03 Amgen Inc. Neurotrophic factor receptors
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
ES2262317T3 (es) * 1998-03-23 2006-11-16 Genentech, Inc. Gfr-alfa3 y sus usos.
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
WO2001016169A2 (en) * 1999-09-01 2001-03-08 Biogen, Inc. RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE
DE602004028801D1 (de) 2003-01-31 2010-10-07 Biogen Idec Inc Neublastin-mutanten
KR102015402B1 (ko) 2010-05-20 2019-08-28 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
US20150177246A1 (en) * 2012-07-26 2015-06-25 Lsip, Llc Fusion gene of cep55 gene and ret gene
EP2992331A4 (en) 2013-04-30 2017-03-29 Université de Montréal Novel biomarkers for acute myeloid leukemia
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087972C (en) 2018-01-18 2023-01-10 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
JP2024522938A (ja) * 2021-06-03 2024-06-21 フンダサン デー．アンナ ジ ソーメル チャンパリマウド エー ドクトル カルロス モンテス チャンパリマウド 脳－脂肪回路を介してｉｌｃ２および肥満度を制御する神経－間葉単位

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4762915A (en) 1985-01-18 1988-08-09 Liposome Technology, Inc. Protein-liposome conjugates
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5185154A (en) 1989-02-02 1993-02-09 Liposome Technology, Inc. Method for instant preparation of a drug containing large unilamellar vesicles
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP3021800B2 (ja) 1990-07-24 2000-03-15 セイコーエプソン株式会社 半導体装置及びその製造方法
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
FR2693107B1 (fr) 1992-07-01 1994-09-23 Chauvin Laboratoire Moyens pour la prévention de la cataracte secondaire.
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
EP0879247A4 (en) * 1995-11-13 2002-01-30 Carlos Ibanez RECEIVERS OF THE NEUROTROPHIC FACTOR DERIVED FROM GLIAL CELL LINES
EP0888385B1 (en) * 1996-03-14 2003-08-20 Genentech, Inc. Gdnf receptor and uses thereof
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides

Also Published As

Publication number Publication date
BG64907B1 (bg) 2006-08-31
WO1997044356A2 (en) 1997-11-27
CZ296516B6 (cs) 2006-04-12
SK152498A3 (en) 1999-08-06
WO1997044356A3 (en) 1998-02-19
EP0914339A2 (en) 1999-05-12
EE9800377A (et) 1999-04-15
KR100587556B1 (ko) 2006-06-08
CN1163509C (zh) 2004-08-25
PT914339E (pt) 2006-12-29
EA199800990A1 (ru) 1999-06-24
CN1232469A (zh) 1999-10-20
NO20065528L (no) 1999-01-08
ES2270465T3 (es) 2007-04-01
NO324957B1 (no) 2008-01-14
ATE335003T1 (de) 2006-08-15
JP2002515743A (ja) 2002-05-28
EA002544B1 (ru) 2002-06-27
IS2361B (is) 2008-05-15
AU732392B2 (en) 2001-04-26
NO985231L (no) 1999-01-08
BG102973A (en) 1999-08-31
IL126918A0 (en) 1999-09-22
KR20050056275A (ko) 2005-06-14
EP1757617A1 (en) 2007-02-28
KR20060024843A (ko) 2006-03-17
BR9710665A (pt) 1999-08-17
CA2253871A1 (en) 1997-11-27
CA2253871C (en) 2005-04-26
EP0914339B1 (en) 2006-08-02
DE69736428T2 (de) 2007-08-30
DK0914339T3 (da) 2006-12-04
DE69736428D1 (de) 2006-09-14
IL126918A (en) 2007-06-03
NO323612B1 (no) 2007-06-18
BG109433A (en) 2007-08-31
NZ332706A (en) 1999-10-28
IS4884A (is) 1998-11-06
SK286115B6 (sk) 2008-03-05
CZ361598A3 (cs) 1999-03-17
AU3472997A (en) 1997-12-09
TR200103297T2 (tr) 2002-06-21
RO120343B1 (ro) 2005-12-30
TR199802252T2 (xx) 1999-02-22
CN1624126A (zh) 2005-06-08

Similar Documents

Publication Publication Date Title
NO985231L (no) Forbindelser som fremmer vevsvekst
EP1439230A3 (en) Human transmembrane protein TMP-2 gene
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
DK0955313T3 (da) Nyt protein og fremgangsmåde til fremstilling af samme
ATE430197T1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
WO1995021919A3 (en) Protein having tpo activity
PT917571E (pt) Gene relacionado com agouti
DE69635738D1 (de) Neuriturin und verwandte wachstumsfaktoren
ATE346083T1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
DE69930662D1 (de) Humane rezeptortyrosinkinase
KR920004571A (ko) 헤파린 결합 향신경성 인자(hbnf)를 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, 및 hbnf의 생성 방법 및 사용방법
ATE192490T1 (de) Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
DE3854420D1 (de) Onkogen kodierendes polypeptid, das wachstumsfaktoraktivität besitzt, verfahren zu seiner herstellung und verwendung.
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
FI954889A7 (fi) Proteiini, jolla on TPO-aktiviteetti
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
MX9504057A (es) Proteina que tiene actividad tpo.
WO2005047316A3 (en) Insulin releasing peptides